Because the phenomenon of no reflow has a poor prognosis in ST-segment elevation myocardial infarction (STEMI) patients and the atherogenic index of plasma (AIP) has been shown to be a strong predictor of coronary heart disease, we aimed to investigate the relationship between AIP and no-reflow in patients with acute STEMI who underwent primary percutaneous coronary intervention (PCI). A total of 763 consecutive STEMI patients (648 men; mean age 58 ± 12 years) who underwent primary PCI were recruited for this study. The patients were classified into a reflow group (n = 537) and a no-reflow group (n = 226) according to the postprocedural angiographic features of thrombolysis in the myocardial infarction flow of the infarct-related artery. The AIP value was significantly higher in the no-reflow group than in the reflow group [0.50 (0.38–0.65) vs. 0.39 (0.25–0.49) p < .001], and AIP was found to be an independent predictor of no-reflow development. The best cut-off value of AIP for predicting no-reflow was 0.54, with sensitivity of 46.02 and specificity of 84,73. In addition, the predictive power of AIP was greater than that of triglycerides and high-density lipoprotein cholesterol based on a receiver operator curve comparison. The AIP was independently associated with no-reflow in patients with STEMI after primary PCI. This might be a superior indicator compared to traditional lipid profiles.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA (2013) ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127(4):529–555
Gupta S, Gupta MM (2016) No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J 68(4):539–551
Niccoli G, Burzotta F, Galiuto L, Crea F (2009) Myocardial no-reflow in humans. J Am Coll Cardiol. 54(4):281–292
Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA (2010) 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 55(21):2383–2389
Deaton C, Froelicher ES, Wu LH, Ho C, Shishani K, Jaarsma T (2011) The global burden of cardiovascular disease. Eur J Cardiovasc Nurs 10(Suppl 2):S5–13
Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A (2002 )Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 25(1):148–198
Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC (2010) Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci 10(3):248–252
Guerin M, Goff Le W, Lassel TS, Tol Van A, Steiner G, Chapman MJ (2001) Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 21(2):282–288
Dobiasova M, Frohlich J (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34(7):583–588
Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G (2015) Atherogenic index of plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran 29:240
Zhan Y, Xu T, Tan X (2016) Two parameters reflect lipid-driven inflammatory state in acute coronary syndrome: atherogenic index of plasma, neutrophil-lymphocyte rati.o BMC Cardiovasc Disord 16:96
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD (2012) Third universal definition of myocardial infarction. Circulation 126(16):2020–2035
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H (2017) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed) 70(12):1082
Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E (2002) Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 105(16):1909–1913
Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP (2001) Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 103(21):2550–2554
Sianos G, Papafaklis MI, Serruys PW (2010) Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol 22(10 Suppl B):6B–14B
Niccoli G, Scalone G, Lerman A, Crea F (2016) Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 37(13):1024–1033
Balta S, Celik T, Ozturk C, Kaya MG, Aparci M, Yildirim AO (2016) The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction. Am J Emerg Med 34(8):1542–1547
Hashemi-Jazi M, Hosseini SM, Gholamrezaei A (2017) Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 13(5):221–229
Bayramoglu A, Tasolar H, Kaya A, Tanboga IH, Yaman M, Bektas O (2018) Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients. J Interv Cardiol 31(2):144–149
Zhou H, He XY, Zhuang SW, Wang J, Lai Y, Qi WG (2014) Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med 5(2):96–102
Sensoy B, Uzunget SB, Acikgoz S, Sensoy N, Sen F, Acar B (2016) Renal dysfunction on admission predicts no-reflow phenomenon in patients undergoing manual thrombus aspiration during primary percutaneous coronary intervention. Acta Cardiol Sin 32(2):185–193
Fajar JK, Heriansyah T, Rohman MS (2018) The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis. Indian Heart J 70(Suppl 3):S406–S418
Anderson KM, Castelli WP, Levy D (1987) Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 257(16)2176–2180
Gentile M, Panico S, Mattiello A, Ubaldi S, Iannuzzo G, De Michele M (2013) Association between small dense LDL and early atherosclerosis in a sample of menopausal women. Clin Chim Acta 426:1–5
Cai G, Shi G, Xue S, Lu W (2017) The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine (Baltimore) 96(37):e8058
Wan K, Zhao J, Huang H, Zhang Q, Chen X, Zeng Z (2015) The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization. PLoS ONE 10(4):e0123521
Sultani R, Tong DC, Peverelle M, Lee YS, Baradi A, Wilson AM (2019) Elevated triglycerides to high-density lipoprotein cholesterol (TG/HDL-C) ratio predicts long-term mortality in high-risk patients. Heart Lung Circ. https://doi.org/10.1016/j.hlc.2019.03.019
Karabag Y, Cagdas M, Rencuzogullari I, Karakoyun S, Artac I, Ilis D (2018) Usefulness of the C-reactive protein/albumin ratio for predicting no-reflow in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur J Clin Invest 48(6):e12928
Schwartz EA, Reaven PD (2012) Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim Biophys Acta 1821(5):858–866
Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD (2012) High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 32(12):2813–2820
Navab M, Reddy ST, Van Lenten BJ, Buga GM, Hough G, Wagner AC (2012) High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol 32(11):2553–2560
Conflict of interest
The authorss declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this articles.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Süleymanoğlu, M., Rencüzoğulları, İ., Karabağ, Y. et al. The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. Int J Cardiovasc Imaging (2020) doi:10.1007/s10554-019-01766-8
- Atherogenic index of plasma
- St-segment elevation myocardial infarction
- Percutaneous coronary intervention